Thomas G. Johnson
University of Sydney
8 Papers
6 Citations
Thomas G. Johnson is an academic researcher from University of Sydney. The author has contributed to research in topics: Gene knockdown & Mesothelioma. The author has an hindex of 4, co-authored 6 publications. Previous affiliations of Thomas G. Johnson include Concord Hospital.
Chat about Author
Papers
Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma
Thomas G. Johnson,Karin Schelch,Yuen Yee Cheng,Marissa Williams,K. Sarun,Michaela B. Kirschner,Steven Kao,Anthony Linton,Anthony Linton,Sonja Klebe,Sonja Klebe,B. McCaughan,Ruby C.Y. Lin,Christine Pirker,Walter Berger,Annette Lasham,Nico van Zandwijk,Glen Reid +17 more
TL;DR: MiR‐137 can exhibit a tumor‐suppressive function in MPM by targeting YBX1, which represents a potential target for novel MPM treatment strategies.
46
Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.
TL;DR: This review will highlight the studies providing evidence for therapeutic effects of modulating microRNA levels in MPM, and discuss these results in the context of emerging approaches to miRNA-based therapy.
31
YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms.
Thomas G. Johnson,Karin Schelch,Kaitao Lai,Kamila A Marzec,Marina L. Kennerson,Marina L. Kennerson,Michael Grusch,Glen Reid,Andrew Burgess,Andrew Burgess +9 more
TL;DR: Data indicates that YB-1 knockdown affects a core set of genes in mesothelioma cells, dependent on the underlying functionality of the STAT3/p53-pathways and the genetic landscape of the cell.
9
Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma.
Xiyong Fan,Chris McLaughlin,Cleo Robinson,Jason Ravasini,K. Schelch,K. Schelch,Thomas G. Johnson,Nico van Zandwijk,Glen Reid,Glen Reid,Anthony M. George +10 more
- 22 Aug 2019
TL;DR: This study suggests that inhibiting the asbestos‐induced generation of reactive oxygen species and stimulating the macrophage system may represent a pathway to amelioration of asbestos‐ induced toxicity.
7
Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo.
Karin Schelch,Dominik Emminger,B. Harboe Zitta,Thomas G. Johnson,Verena Kopatz,Sebastian Eder,Alexander Ries,Alessia Stefanelli,Petra Heffeter,Mir Alireza Hoda,Konrad Hoetzenecker,Balazs Dome,Walter Berger,Glen Reid,Michael Grusch +14 more
TL;DR: It is demonstrated that targeting YB-1 via entinostat is a promising approach to enhance cisplatin and radiation sensitivity, and in a mouse model, the combination of cisPlatin and entInostat resulted in stronger growth inhibition than each treatment alone.
6